In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Alzheimer disease (AD) is an irreversible brain disorder associated with slow, progressive
loss of brain functions mostly in older people. The disease processes start years before …

Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Animal models of human diseases that accurately recapitulate clinical pathology are
indispensable for understanding molecular mechanisms and advancing preclinical studies …

Background The growing body of evidence indicating the heterogeneity of Alzheimer's
disease (AD), coupled with disappointing clinical studies directed at a fit-for-all therapy …

Alzheimer's disease (AD) is the foremost type of dementia that afflicts considerable morbidity
and mortality in aged population. Several transcription molecules, pathways, and molecular …

Abstract The original Human Connectome Project yielded a rich data set on structural and
functional connectivity in a large sample of healthy young adults using improved methods of …

Alzheimer's disease (AD) is a debilitating, chronic neurodegenerative disease. Genetic
studies involving genome-wide association studies (GWAS) and meta-analysis have …

Alzheimer's disease (AD) is a neurodegenerative disorder that causes cognitive decline,
memory loss, and inability to perform everyday functions. Hallmark features of AD …